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Abstract
The cardioprotective effects of high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A1 (apoA-I) are well
documented, but their effects in the direction of the cardiac differentiation of embryonic stem cells are unknown.
We evaluated the effects of exogenous apoA-I expression on cardiac differentiation of ESCs and maturation of ESC-
derived cardiomyocytes. We stably over-expressed full-length human apoA-I cDNA with lentivirus (LV)-mediated
gene transfer in undifferentiated mouse ESCs and human induced pluripotent stem cells. Upon cardiac
differentiation, we observed a significantly higher percentage of beating embryoid bodies, an increased number
of cardiomyocytes as determined by flow cytometry, and expression of cardiac markers including a-myosin heavy
chain, b-myosin heavy chain and myosin light chain 2 ventricular transcripts in LV-apoA-I transduced ESCs compared
with control (LV-GFP). In the presence of noggin, a BMP4 antagonist, activation of BMP4-SMAD signaling cascade in
apoA-I transduced ESCs completely abolished the apoA-I stimulated cardiac differentiation. Furthermore, co-
application of recombinant apoA-I and BMP4 synergistical l yi n c r e a s e dt h ep e r c e n t a g eo fb e a t i n gE B sd e r i v e df r o m
untransduced D3 ESCs. These together suggests that that pro-cardiogenic apoA-I is mediated via the BMP4-SMAD
signaling pathway. Functionally, cardiomyocytes derived from the apoA-I-transduced cells exhibited improved
calcium handling properties in both non-caffeine and caffeine-induced calcium transient, suggesting that apoA-I
plays a role in enhancing cardiac maturation. This increased cardiac differentiation and maturation has also been
observed in human iPSCs, providing further evidence of the beneficial effects of apoA-I in promoting cardiac
differentiation. In Conclusion, we present novel experimental evidence that apoA-I enhances cardiac differentiation
of ESCs and iPSCs and promotes maturation of the calcium handling property of ESC-derived cardiomyocytes via the
BMP4/SMAD signaling pathway.
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Introduction
Pluripotent stem cells, including embryonic stem cells (ESCs)
and induced pluripotent stem cells (iPSCs), can differentiate into
virtually all cells of the body including cardiomyocytes. They thus
represent an unlimited ex-vivo cell source for cardiac regenerative
therapy [1]. Spontaneous differentiation of pluripotent stem cells
toward cardiac lineage is nonetheless inefficient, and the resultant
cardiomyocytes display immature electrophysiological and calci-
um handling properties [2,3,4]. These immaturities result in
ineffective contractile force generation and may also create
arrhythmogenic substrates. This raises potential safety concerns
for cell-based cardiac therapy [1,5].
High-density lipoprotein-cholesterol (HDL-C) and its princi-
ple component, apolipoprotein A-1 (apoA-I), have been
consistently demonstrated by large prospective epidemiological
studies to be two of the most powerful independent negative
predictors of cardiovascular ev e n t s[ 6 , 7 ] .W i t he a c h1m g / d L
increment of HDL-C, there is a 2 to 3% reduction in risk of
coronary artery disease [6,7]. The beneficial effects of HDL-C/
apoA-I are mainly attributed to its role in reversal of cholesterol
transport and in regulation of endothelial cell proliferation and
migration [8,9]. This in turn reduces atherosclerotic progres-
sion. Recent evidence indicates that HDL-C/apoA-I exerts
direct protective effects on adult cardiomyocytes under various
stresses through signal pathways that are unrelated to choles-
terol transportation [10,11,12]. It has been previously reported
t h a tf e t a lc a r d i o m y o c y t e sa sw e l la st h e i ra d u l tc o u n t e r p a r t s
express apoA-I, although the physiological significance remains
largely unknown [13,14]. We evaluated the hypothesis that
h u m a na p o A - Ig e n e - t r a n s f e rm a ye nhance cardiac differentia-
tion of pluripotent stem cells (murine ESCs and human iPSCs)
and facilitate the maturation of calcium handling properties of
their cardiac derivatives. Our data indicate a direct cardiogenic
effect of apoA-I gene-transfer on mouse ESCs and human iPSCs
v i aaB M P 4 / S M A Ds i g n a l i n gp a t h w a y .
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Exogenous apoA-I expression promotes cardiac
differentiation of mouse ESCs
To evaluate the effects of apoA-I on cardiac differentiation of ESCs,
we first constructed pHRST-CMV-apoA-I-IRES-GFP (pLV-apoA-I)
that allowed simultaneous expression of full-length cDNA of human
apoA-I and GFP under the control of CMV promoter. We confirmed
the efficacy of our LV-apoA-I construct to mediate exogenous
expression of apoA-I in undifferentiated ESCs. Figure 1A shows that
transduction of undifferentiated ESCs after lentivirus-mediated gene
transfer, (1) LV-apoA-I, and (2) LV-GFP, enabled generation of ESC
lines that stably expressed GFP. In addition, apoA-I protein
(,30 kDa) was detected in the medium of LV-apoA-I transduced
undifferentiated ESCs but not the LV-GFP counterpart (Figure 1B).
After confirming the effectiveness of gene transfer, in vitro cardiac
differentiation was assessed and confirmed when spontaneous beating
embryoid bodies were visualized under microscopic and flow
cytometry analysis. Although spontaneously beating outgrowths were
observed in both LV-GFP- and LV-apoA-I -transduced ESCs as
early as day 1, LV- apoA-I-transduced ESCs had a persistently and
significantly higher percentage of embryoid bodies containing
spontaneously beating outgrowths than LV-GFP-transduced ESCs
from day 3 to day 7 (9664% vs. 4563%, p,0.005)(Figure 2A).
Although a commonly used method, counting of beating outgrowths
from embryoid bodies is nonetheless a very crude means of assessing
cardiac differentiation [15]. To further confirm that LV-apoA-I
enhanced cardiac differentiation, flow cytometry to determine the
percentage of cardiomyocytes as identified by troponin-T positive
cells was performed on day 8. The percentage of cardiomyocytes was
consistently and significantly higher in LV-apoA-I transduced ESCs
than in LV-GFP transduced cells (1262% vs. 461%; p,0.05)
(Figure 2B). Furthermore, the morphology of LV-GFP-transduced
ESC-derived cardiomyocytes was round-shaped and of shorter
length, whereas LV- apoA-I-transduced ESC-derived cardiomyo-
cytes were rod-shaped with long tapering ends and an extensive
coverage of myofibrils, resembling the morphology of adult murine
ventricular cardiomyocytes.(Figure 2C) [16,17]. Real-time quantita-
tive PCR consistently revealed that the expression of a panel of
cardiac marker genes was significantly up-regulated in LV-apoA-I-
transduced ESCs compared with LV-GFP-transduced ESCs,
including a-MHC (4.3 fold, p,0.005), b-MHC (1.4 fold, p,0.05)
and MLC2v (4.4 fold, p,0.005) (Figure 2D).
apoA-I activates BMP4-SMAD1/5 signaling pathway in
ESCs
In addition to its well recognized role in reverse cholesterol
transport, HDL-C/apoA-I has been recently demonstrated to exert
its effects on aortic endothelial cells by modulating expression of
activin-like kinase receptors (ALK)1 and ALK2, thereby regulating
BMP4 signaling [18]. It has been previously shown that BMP4
regulates cardiac differentiation of ESCs via the BMP/SMAD
signaling pathway [19,20,21]. Therefore we also studied the ALK/
BMP signaling pathway in apoA-I-enhanced cardiac differentiation
of ESCs. Figure 3A shows that the mRNA levels of BMP4, ALK1
and ALK2 were significantly enhanced in LV-apoA-I-transduced
ESCs compared with LV-GFP-transduced ESCs as determined by
real-time quantitative PCR analysis. This suggests that apoA-I may
activate BMP4 signaling at transcriptional levels. To corroborate
and extend these observations, we performed Western blot analysis
for SMAD signaling pathway: LV-apoA-I transduction in ESCs
resulted in increased pSMAD1/5 signals, which was totally absent
in LV-GFP-transduced ESCs (Figure 3B). To confirm this
observation, another antibody against pSMAD1/5/8 was used.
Similar result was observed except that trace amount of pSMAD1/
5/8 could also be detected in the LV-GFP group (Figure 3B). Of
note, the total SMAD2 protein level was significantly reduced in
LV-apoA-I transduced ESCs compared with LV-GFP; there was
nonetheless no statistically significant difference in pSMAD2/
SMAD2 between these two groups (Figure 3B and C). In addition,
no significant differences in levels of total SMAD4, SMAD5,
SMAD1/5/8 and SMAD6 between LV-apoA-I and LV-GFP
transduced ESCs were detected (Figure 3B and C).
BMP4 inhibition abolished apoA-I stimulated cardiac
differentiation of ESCs
To confirm the involvement of a BMP4-SMAD signalingcascade
in apoA-I-enhanced cardiac differentiation of ESCs, a BMP
antagonist, noggin (1 ng/ml) that known to inhibit BMP-mediated
cardiac differentiation [22,23,24], was added to differentiating LV-
Figure 1. Expression of human apoA-I in D3 mouse ESCs.
Undifferentiated ESCs were cultured in the absence of a feeder layer
and transduced with lentiviral particles containing the full-length wild
type apoA-I cDNA under the control of CMV promoter. This expression
cassette was linked to the IRES-GFP reported cassette for the
identification of transduced cells, while the lentiviral particles contain-
ing the empty construct served as a control. To evaluate the success of
gene transfer, undifferentiated empty construct- and apoA-I-transduced
cells were examined for expression of GFP (A). The secretion of apoA-I
in the concentrated spent medium was determined by Western blot
analysis using an antibody specific to apoA-I.
doi:10.1371/journal.pone.0019787.g001
APOA1 Promote Cardiac Differentiation of ESCs
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19787apoA-I-transduced ESCs. As shown in Figure 4, the application of
noggin completely abrogated SMAD1/5 phosphorylation. Similar
results were observed when another antibody against pSMAD1/5/
8 was used despite trace amount of pSMAD1/5/8 could be
observed in the LV-apoA-I+Noggin group (Figure 4A). On the
other hand, there was no obvious change in the total protein
amounts of SMAD5 and SMAD1/5/8 between the two groups
(Figure 4A). In additions, noggin also abolished the LV-apoA-I
Figure 2. Effect of apoA-I gene transfer on generation of beating embryoid body and cardiac cells. (A) Empty construct and apoA-I-
transduced mouse ESCs were differentiated using the conventional ‘‘hanging-drop’’ method, and the resultant embryoid bodies (EBs) were plated
onto gelatin coated plates. The occurrence of beating areas within the EBs was observed and counted for 8 days starting from the day of plating. (B)
Percentage of ESC-derived cardiomyocytes (troponin-T positive cells) on day 8 as determined by flow cytometry. (C) Individual cardiomyocytes were
isolated from the beating area of the EBs and identified with immunnohistochemistry using antibody specific to the cardiac troponin-T. (D) Cardiac
maker gene expression in the embryoid bodies derived from empty construct- and apoA-I-transduced ESCs as revealed by real-time quantitative PCR
analysis. MHCA: a-myosin heavy chain; MHCB: b-myosin heavy chain; MLC2V: myosin light chain 2 ventricular transcripts. Data shown as mean 6 SEM
from at least 3 independent experiments, n=3–5, *p,0.05; **p,0.005.
doi:10.1371/journal.pone.0019787.g002
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percentage of embryoid bodies containing beating outgrowths
(from 9664% to 4666%, p,0.005) and the number of troponin-T
positive cells (from 1262% to 562%, p,0.05) back to the control
(LV-GFP) level (Figure 4B and C).
Co-application of recombinant apoA-1 and BMP4
synergistically increases cardiac differentiation of ESCs
To demonstrate the synergetic effects of apoA-1 and BMP4 on
promoting the cardiac differentiation of ESCs, untransduced D3
ESCsweredifferentiated inthe presenceorabsenceofeitherofboth
of the above factors. As showed in Figure 5, application of
recombinant human apoA-1, but not BMP4 alone, only moderately
increased the production of beating EBs, however, co-application of
both factors significantly increased the presentage of beating EBs
(,5 fold, p,0.005). This clearly demonstrated that apoA-I
promotesthe cardiacdifferentiation viatheBMP4 signallypathway.
Maturation of calcium handling properties with apoA-I
transduction
Spontaneous calcium oscillations in single cardiomyocytes were
characterized with confocal microscope-based calcium transient
Figure 3. apoA-I gene transfer activates the BMP4-SMAD1/5 signaling cascade in undifferentiated ESCs. (A) The mRNA levels of bone
morphogenic protein 4 (BMP4), activin receptor-like kinase 1 (ALK1) and activin receptor-like kinase 2 (ALK2) in the undifferentiated ESCs transduced
with empty construct or apoA-I were evaluated by real-time quantitative PCR analysis using ribosomal protein S16 as internal control. (B) The
phosphorylation status and total protein levels of the SMAD proteins were evaluated with Western blot analysis using b-actin as loading control. (C)
The densitometry quantification of the Western blot results. Data shown as mean 6 SEM from 3 independent experiments,* p,0.05; ** p,0.005.
doi:10.1371/journal.pone.0019787.g003
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differentiation could influence the maturation of ESC-derived
cardiomyocytes. While spontaneous calcium transients were
observed in both LV- apoA-I- and LV-GFP-transduced ESC-
derived cardiomyocytes, LV- apoA-I-transduced cells exhibited
more mature calcium handling properties compared with their
LV-GFP counterpart (Figure 6). Specifically, the amplitudes of
calcium transient in LV-apoA-I-transduced ESC-derived cardio-
myocytes, determined using a fluorescence intensity (F/F0) value
measured against time, were 1.7 fold larger than those in LV-GFP-
transduced counterpart (p,0.005)(Figure 6A and B). In kinetic
analysis, LV-apoA-I-transduced ESC-derived cardiomyocytes had
faster upstroke (LV-GFP: 16.661.8, n=21 vs. LV-apoA-I:
27.761.6, n=30, p,0.005) and decay velocities (LV-GFP:
214.261.9, n=21 vs. LV-apoA-I: 226.361.5, n=30, p,0.005)
(Figure 6C and D). In addition brief exposure to caffeine (10 mM)
that evaluated the calcium storage capacity of sarcoplasmic
reticulum (SR) induced a robust surge in cytosolic calcium in
both LV-apoA-I- and LV-GFP-transduced ESC-derived cardio-
myocytes. This suggests the presence of a functioning internal
calcium store (Figure 6E and F). The caffeine-induced calcium
transient in LV-apoA-I-transduced ESC-derived cardiomyocytes
nonetheless had a significantly larger amplitude (LV-GFP:6.160.5
vs. LV-apoA-I:13.161.1 F/F0, p,0.005)(Figure 6F), higher
maximal upstroke velocity (LV-GFP 1.760.3 vs. LV-apoA-
I:3.060.4 F/F0/s, p,0.05)(Figure 6G), and maximal decay
velocity (LV-GFP: 20.360.1 vs. LV-apoA-I: 20.660.1 F/F0/s,
p,0.05)(Figure 6H), compared with LV-GFP-transduced ESC-
derived cardiomyocytes. This indicates a substantial increase in
SR calcium content conferred by apoA-I transduction. To
understand the mechanisms for these improvements in calcium
handling, the expression of a panel of calcium handling proteins
was determined using real-time quantitative PCR analysis
(Figure 7). Consistent with the confocal calcium imaging result,
Figure 4. Inhibition of the BMP4 signaling pathway abolished the pro-cardiogenic effects of apoA-I gene transfer. The BMP4 signaling
pathway was inhibited by the application of noggin (1 m/ml) to the apoA-I- transduced ESCs upon plating. (A) The phosphorylation status of the
differentiating cells was evaluated 24 hr after noggin treatment. (B) The appearance of beating clusters during the 8-day period of differentiation. (C)
The percentage of troponin-T positive cells as determined by flow cytometry analysis. Data shown as mean 6 SEM from 3 independent experiments,
# p,0.05 comparing to the LV-apoA-I group; *p,0.05 and ** p,0.005 comparing to the LV-GFP group.
doi:10.1371/journal.pone.0019787.g004
Figure 5. Synergistic effect of recombinant apoA-I and BMP4
on the cardiac differentiation of D3 ESCs. Untransduced D3 ESCs
were subjected to cardiac differentiation in the presences or absence of
recombinant apoA-1 (100 nM) and/or BMP4 (0.5 ng/ml). The appear-
ance of beating clusters during the 8-day period of differentiation were
recorded. Data shown as mean 6 SEM from 3 independent
experiments, ** p,0.005 comparing to the control group.
doi:10.1371/journal.pone.0019787.g005
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PLoS ONE | www.plosone.org 5 May 2011 | Volume 6 | Issue 5 | e19787Figure 6. Calcium handling property of the cardiomyocytes derived from empty construct- and apoA-I-transduced ESCs. (A)
Representative tracings of rhythmic spontaneous Ca2+ transients in cardiomyocytes derived from empty construct- and apoA-I- transduced cells. (B):
Amplitude, (C) Maximal upstroke velocity (Vmax upstroke), (D) Maximal decay velocity (Vmax decay) of Ca2+ transients in the mESC-derived
cardiomyocytes. (E) Representative tracings of caffeine-induced Ca2+ release from sarcoplasmic reticulum in cardiomyocytes derived from wild type,
empty construct and apoA-I-1a transduced cells (right), demonstrating caffeine-sensitive Ca2+ stores and fractional release of total sarcoplasmic
reticulum Ca2+ load during spontaneous activation. (F): Amplitude, (G) Maximal upstroke velocity (Vmax upstroke), (H) Maximal decay velocity (Vmax
decay) of Ca2+ transients in the ESC-derived cardiomyocytes. Data shown as mean 6 SEM from the recordings of 20–30 cells from 3–5 independent
experiments, * p,0.05; ** p,0.005.
doi:10.1371/journal.pone.0019787.g006
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+-Ca
2+
exchanger (NCX)-1 (1.4 fold, p,0.005), sarco/endoplasmic
reticulum Ca
2+-ATPase (SERCA)-2a (1.6 fold, p,0.005), and
ryanodine receptor (RyR)-2 (1.3 fold, p,0.005) compared with
LV-GFP-transduced ESCs (Figure 7).
Exogenous apoA-I expression promotes cardiac
differentiation of human iPSCs
To determine whether enhanced expression of apoA-I exerts
similar effects on other types of pluripotent stem cells, human
iPSCs (line IMR90) transduced with LV-GFP or LV-apoA-I
pseudoviral particles were subjected to cardiac differentiation.
Although the transduction efficiency for IMR90 was much lower
than that of D3 mouse ESCs (data not shown), LV-apoA-I
transduction obviously increased the cardiac differentiation
potential of IMR90. This was demonstrated by flow cytometery
where LV-apoA-I transduction significantly increased the per-
centage of a- actinin (sarcomeric) positive cells from 1061% to
1661% (p,0.005) (Figure 8A). In addition, immunohistochemis-
try revealed that the numbers of cardiac troponin-T positive cells
obviously increased in embryoid bodies derived from LV-apoA-I
transduced groups (Figure 8B).
Exogenouse apoA-I expression improves calcium
homeostasis of human iPSC-derived cardiomyocytes
The calcium handling properties of human iPSC-derived
cardiomyocytes were also evaluated by confocal microscope. As
shown in figure 9A and B, cardiomyocytes derived from LV-apoA-
I transduced human iPSCs exhibited more mature calcium
handling properties including a larger amplitude (LV-GFP:10.76
1.2 vs. LV-apoA-I:15.961.2 F/F0, p,0.005, n=15), and higher
maximal upstroke velocity (LV-GFP 13.661.6 vs. LV-apoA-
I:28.662.2, F/F0/s, p,0.05, n=15) and maximal decay velocity
(LV-GFP: 27.060.9 vs. LV-apoA-I: 219.661.7, F/F0/s,
p,0.05, n=15), compared with LV-GFP-transduced ESC-
derived cardiomyocytes. Unlike mESC-derived cardiomyocytes,
human iPSC-derived cardiomyocytes (both LV-GFP and LV-
apoA-I groups) were not responsive to caffeine. Nonetheless,
application of 10 mM of ryanodine, a ryanodine receptor blocker,
substantially reduced the amplitude (approximately 60% reduction
compared with drug-free recordings, n=15) and upstroke values
(approximately 60% reduction compared with drug-free record-
ings, n=15) of spontaneous calcium transients in the cardiomy-
ocytes derived from the LV-apoA-I transduced group (Figure 9A
and C). In contrast, cardiomyocytes derived from LV-GFP
transduced human iPSCs exhibited only a modest response to
ryanodine (,20% reductions in both amplitude and upstroke
value of calcium transients) suggesting a more immature calcium
handling apparatus.
Discussion
To our knowledge, this is the first systematic study to evaluate
the effects of apoA-I on cardiac differentiation of ESCs and human
iPSCs. Our results demonstrate that exogenous expression of
apoA-I promotes cardiac differentiation of pluripotent stem cells
and enables maturation of calcium handling properties of
pluripotent stem cell-derived cardiomyocytes. The main findings:
(1) apoA-I over-expression promotes cardiac differentiation of
mouse ESCs (in terms of the percentage of beating outgrowths, the
number of cardiomyocytes as determined by flow cytometry), (2)
apoA-I over-expression increases cardiac specific gene expression
during ESC differentiation; (3) apoA-I-induced cardiac differen-
tiation is dependent on a BMP4-SMAD1/5 signaling cascade; (4)
apoA-I over-expression enhances the expression of calcium
handling proteins (RyR2, NCX-1 and SERCA-2a) with a
corresponding maturation of calcium handling properties in
ESC-derived cardiomyocytes; (5) the cardiogenic effects of apoA-
I are also observed in human iPSCs.
Accumulating evidence suggests that apoA-I plays a critical role
not only in maintaining normal endothelial function [25,26] but
also in protecting cardiomyocytes from various types of insults
including ischemic and re-perfusion injury [11], doxorubicin
induced cardiomyocytes [10], and diabetic cardiomyopathy [12]
through alternative mechanisms unrelated to cholesterol transpor-
tation. According to the current knowledge, the cardioprotective
effects of apoA-1 and HDL-C appears to be largely contributed by
its anti-inflammatory, anti-oxidative and anti-apoptotic action. In
the present study, our data show that apoA-I is one of the
upstream modulators of the BMP4 signaling pathway by
concomitant up-regulation of expression of BMP4, and its
receptors (ALK1 and ALK2), which in turn activates the
SMAD1/5 signaling cascade. This apoA-I induced cardiac
differentiation is mediated, at least in part, via this enhancement
of BPM4 signaling, as evidenced by its complete abolition
following application of noggin, an antagonist for BMP4, while
co-application of recombinant apoA-1 and BMP4 synergistically
promotes the cardiac differentiation of untransduced D3 ESCs.
Similarly, Yao and co-workers have recently demonstrated in
human aortic endothelial cells that HDL-C/apoA-I enhances
BMP-signaling system by promoting expression of ALK2, a BMP-
receptor, thus resulting in increased vascular endothelial growth
factor (VEGF) and matrix Gla protein (MGP), essential for
endothelial cell survival and prevention of vascular calcification,
respectively [18]. This provides a mechanistic link between the
HDL-C/apoA-I and BMP4 signaling pathway. As a member of
the transforming growth factor (TGF)-b superfamily of proteins,
BMPs play an important role in organogenesis of the cardiovas-
cular system [22,23] and tissue regeneration following injury [27].
Mechanistically, BMPs interacts with the membrane surface
receptors, such as ALK1 and ALK2, and mediates the kinase
activities of these receptors [27,28]. This leads to the phosphor-
ylation of receptor mediated-SMAD proteins, such as SMAD1,
SMAD5 and SMAD8 [29,30,31,32]. The phosporylated SMAD
proteins then bind with SMAD4 to form the SMAD transcription
Figure 7. The expression of calcium handling components in
cardiomyocytes. The mRNA levels of sodium/calcium exchanger
(NCX1), sarcoplasmic reticulum Ca2+ ATPase (SERCA2A) and ryanodine
receptor 2 (RYR2) of embryoid bodies (at d8 after plating) were
evaluated by real-time quantitative PCR analysis using ribosomal
protein S16 as internal control. Data shown as mean 6 SEM from 3
independent experiments, ** p,0.005.
doi:10.1371/journal.pone.0019787.g007
APOA1 Promote Cardiac Differentiation of ESCs
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e19787factor complex which translocates into the nucleus and bind to the
consensus DNA sequence to regulate the BMP target gene
transcriptions [30,32]. BMP4 and SMAD5 are critical to
mesoderm formation and angiogenesis respectively.[27,33,34]
BMPs has also been repeatedly shown to play an important role
in cardiogenesis not only in embryonic stem cells, [19,20,21,
35,36,37], but also to promote c-kit positive bone marrow cells to
adopt a cardiac fate [38,39].
In adult cardiomyocytes, cyclic intracellular calcium transients
underlying the excitation-contraction coupling are triggered by a
process known as calcium-induced calcium release. During systole,
a relative small calcium influx enters cells through L-type calcium
channels and triggers a large calcium release from the internal
calcium store, SR, through ryanodine receptors [40]. During the
diastolic phase, cytosolic calcium is actively removed mainly
through SERCA-2a back into SR and NCX-1 out of cells [41].
ESC-derived cardiomyocytes are nonetheless known to exhibit
immature calcium dynamics including small cytosolic calcium
transient amplitudes, slow rise and decay kinetics, and reduced
calcium content of SR [3,4,41,42,43]. This is partly related to the
underdeveloped SR and partly to the developmental expression
profiles of calcium handling proteins in ESC-derived cardiomy-
ocytes [3,42]. In the present study, LV-apoA-I-transduced ESCs
and iPSC-derived cardiomyocytes exhibited more mature calcium
handling properties including larger calcium transients, and a
faster rate of rise and decay of calcium transients. In addition, the
LV-apoA-I-transduced ESC-derived cardiomyocytes appeared to
have a larger internal store of calcium as evidenced by a larger
amplitude of caffeine-mediated calcium release or ryanodine
responsiveness. These improvements were associated with up-
regulation of certain key calcium handling proteins (RyR2, NCX-
1 and SERCA-2a). Mechanistically, the more mature calcium
handling properties of LV-apoA-I-transduced mouse ESC-derived
cardiomyocytes or human iPSC-derived cardiomyocytes may be
due to accelerated cardiac differentiation or the direct effects of
apoA-I on the cardiomyocytes and we are interesting in
delineating between these two possibilities in the further study.
In summary, although the cardioprotective effects of apoA-I and
HDL-C is well documented, little is known about its effects on the
cardiac regeneration from pluripotent stem cells. By revealing role
of apoA-I in promoting the cardiac differentiation of ESCs and
iPSCs and the involvement of BMP4 signaling cascade, our study
provided new insights for the therapeutic values of apoA-I gene
transfer in regenerative medicine. First, the human iPSCs-derived
cardiomyocytes that stably expressing the apoA-I is expected to be
a functionally improved cell sources for transplantation, more
importantly, after transplantation, these cells may act as an
internal sources of the apoA-I that may lead to the increased local
HDL-C levels in the infarct sites that could be beneficial to the
recovery of myocardial infraction.
Materials and Methods
Ethics Statement
The present study was conducted entirely on commercially
available cell-lines, no human participants or animals were
involved, as such, ethics approval was not required for the present
study.
Figure 8. Effect of apoA-I gene transfer on the cardiac differentiation of IMR90 human IPSCs. (A) Percentage of ESC-derived
cardiomyocytes (a-actinin (sarcomeric)-positive cells) 30 days after plating as determined by flow cytometry. (B) The beating EBs were digested into
monolayers and the cardiomyocytes were identified with immunnohistochemistry using antibody specific to the cardiac troponin-T. Data shown as
mean 6 SEM from at least 3 independent experiments, *p,0.05; **p,0.005. Scale bar=50 mm.
doi:10.1371/journal.pone.0019787.g008
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A murine ESC-line D3 (CRL-1934, American Type Culture
Collection, Manassas, VA) was used in this study and cultured on
irradiation-inactivated mouse embryonic feeders as previously
described [2,4,44]. To induce cardiac differentiation, embryoid
bodies (,800 ESCs in 20 mL culture medium in the absence of
leukemia inhibitory factors) were formed using a hanging drop
method followed by 7 days in suspension culture. After the
hanging drop stage, the embryoid bodies were then plated onto
0.1% gelatin-coated tissue culture dishes [2,4,44]. Whenever
necessary, recombinant human apoA-I (100 nM) (Sigma-Aldrich,
St. Louis, MO), bone morphogenetic protein-4 (BMP4) (0.5 ng/
ml) or noggin (1 mg/ml), an inhibitor of the bone morphogenetic
protein (BMP)-pathway, was supplemented during differentiation.
Human iPSC culture and cardiac differentiation
Undifferentiated human iPSCs (IMR90, WiCell Research
Institute, Madison, Wisconsin, USA) were maintained in a
serum-free and feeder-free culture system (StemPro hESC SFM
system) (Invitrogen Gibco) according to the manufacture’s
instructions. When 80% confluence was reached, cells were
treated with dispase (1 mg/ml) for 5 minutes at 37uC followed by
Figure 9. Calcium homeostasis in the cardiomyocytes derived from IMR90 (LV-GFP and LV-apoA-I). (A) representative tracings of the
calcium transient in the absence (control) or presence of ryanodine. (B) statistical analysis of the amplitude, calcium release rate and calcium re-
uptake rates of the IMR90-derived cardiomyocytes in the absence of Ryanodine. (C) amplitudes and calcium release rates after ryanodine application
normalized to values recorded under control ryanodine-free conditions. Data shown as mean 6 SEM from the recordings of 15 cells from 3–5
independent experiments, ** p,0.005.
doi:10.1371/journal.pone.0019787.g009
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embryoid bodies in suspension culture with StemPro hESC
medium for 5 days. Embryoid bodies were then plated onto
gelatin-coated plates in a basal medium (StemPro34, Invitrogen)
supplemented with 2 mM glutamine, 4 mM monothioglycerol,
50 mg/ml ascorbic acid, and 0.5 ng/ml BMP4 according to a
previous protocol [21].
Lentivirus-mediated gene transfer
To exogenously express apoA-I in murine ESCs and human
iPSCs, full-length cDNA of human apoA-I obtained from
Origene (SC 110828, Origene technologies, Rockville, MD)
was subcloned into the lentiviral vector pHRST-CMV-IRES-
GFP (pLV-GFP) with blunt-end-ligation to generate pHRST-
CMV-apoA-I-IRES-GFP (pLV-apoA-I). The constitutively active
CMV promoter enables transgene expression in all cell types in
both undifferentiated and differentiated states. The internal
ribosomal entry site (IRES) allows the simultaneous translation
of two transgenes with a single transcript and, in our experiments,
green fluorescence protein and an apoA-I construct. The
production of lentiviruses has been described previously [44].
Briefly, the lentiviral vector constructs (pLV-apoA-I and pLV-
GFP (empty cassette)) were co-transferred with the virus-
packaging plasmid (pCMV-dR8.91) and envelope plasmid
(pMD2G) into HEK293FT cells (Invitrogen) with lipofectamine
2000 (Invitrogen) mediated transfection. The supernatant was
collected 48 hours after transfection and concentrated by high-
speed centrifugation (20,000 g for 2 hours at 4uC). For transduc-
tion, undifferentiated mouse ESCs and human iPSCs were
incubated with 50 ul supernatant without feeder cells for
12 hours.
Flow cytometry analysis
The percentage of ESC-derived cardiomyocytes was quantified
using flow cytometry analysis on day 7 after plating for mouse
ESCs and on day 30 for human iPSCs. Briefly, embryoid bodies
were dissociated to single cells with collagenase B (1 mg/ml).
Cells were fixed and permeabilized using a Cytofix/Cytoperm
permeabilization kit (BD Biosciences, San Diego, CA), and
stained with monoclonal anti-troponin T antibody (dilution
1:100; NeoMarker, Fremont, CA) or monoclonal anti-a-actinin
(sarcomeric) antibody (A7811,dilution 1:100; Sigma) followed by
a secondary antibody, anti-mouse IgG H+L-PE (dilution 1:100;
Beckman Coulter, Fullerton, CA, USA). Analysis was performed
using a Beckman Coulter FC500 flow cytometer. The primary
antibody, IgG1, was used as an isotypic control to determine
background signal.
Real-time quantitative polymerase chain reaction analysis
Total RNA was isolated and reverse transcribed using an
Ilustra RNAspin Mini Kit (GE healthcare). Reverse transcription
(RT) was performed with 0.5 mg of total RNA using a
QuantiTectH reverse transcription kit (Qiagen, Hilden, Germany)
according to the manufacturer’s instructions. Oligonucleotides of
the genes of interest in quantitative polymerase chain reaction
(PCR) are listed in Table 1. Quantitative PCR analysis was
performed with DNA engine opticon 2 real-time PCR detection
system (Bio-Rad, Hercules, USA) using iQ SYBR Green
Supermix (Bio-Rad, Hercules, USA). The relative quantification
of the PCR products was performed according to the 2
2DDCt
method, using mouse ribosomal protein S16 (S16) as an
internal control, where DDCt=[(Cttarget gene2CtS16)LV-apoA-I2
(Ct target gene2Ct S16)LV-GFP].
Western blot analysis
TotalproteinswereextractedfromundifferentiatedESCsand/or
embryoid bodies using a lysis buffer containing 1% Triton X-100,
1% sodium deoxycolate, 0.1%SDS, 150 mM sodium chloride, and
10 mM sodiumphosphate, at pH 7.2. Protein(20 mg) was loaded in
a 10% SDS page, and electrically transferred onto a PVDF
membrane that was probed with the antibodies listed in Table 2.
Detection was performed with a standard ECL based system.
Immunofluorescence staining
Beating embryoid bodies from mouse ESCs and human iPSCs
were dissociated, plated onto glass coverslips, and fixed with 2%
paraformaldehyde for 48 hours at 4uC. After fixation, cells were
washed twice with PBS and incubated in a blocking buffer (2%
BSA, PBS, 0.1% Triton-X100) for 2 hours. Cells were then
incubated with murine monoclonal anti-troponin T (dilution
1:100; NeoMarker, Fremont, CA) at 4uC overnight. After removal
of unbound antibodies with washing buffer, cells were incubated
with Alexa-488 conjugated anti-rabbit secondary antibodies
(Invitrogen) (1:100 dilution in washing buffer) for 1 hour at room
temperature. Cells were then mounted on glass slides with a
mounting medium containing DAPI. Presence of the immune-
complex was examined using fluorescent microscopy.
Table 1. Primers used in the real-time quantitative RT-PCR
analysis.
Genes of interest Sequence 59R39
BMP4 Forward TCGTTACCTCAAGGGAGTGG
Reverse ATGCTTGGGACTACGTTTGG
ALK1 Forward GTCAAGAAGCCTCCAGCAAC
Reverse CCTTGTCTCTTGCCTGAACC
ALK2 Forward GATACGGTTAGCTGCCTTCG
Reverse TGCAGCACTGTCCATTCTTC
MHC-A Forward GATGCCCAGATGGCTGACTT
Reverse GGTCAGCATGGCCATGTCCT
MHC-B Forward GCCAACACCAACCTGTCCAAGTTC
Reverse TGCAAAGGCTCCAGGTCTGAGGGC
MLC2V Forward TTCTCAACGCATTCAAGGTG
Reverse CTGGTCGATCTCCTCTTTGG
GATA4 Forward TCTCCCAGGAACATCAAAACC
Reverse GTGTGAAGGGGTGAAAAGG
Nkx2.5 Forward GCTACAAGTGCAAGCGACAG
Reverse GGGTAGGCGTTGTAGCCATA
NCX1 Forward TGTGTTTACGTGGTCCCTGA
Reverse CTCCACAACTCCAGGAGAGC
SERCA2A Forward GATCACACCGCTGAATCTG
Reverse AGTATTGCGGGTTGTTCCAG
RYR2 Forward TCTTAGCCATCCTCCACACC
Reverse TCCGTCAAACTCCAACTTCC
S16 Forward CATCTCAAAGGCCCTGGTAG
Reverse CCAAACTTTTTGGATTCGCA
Abbreviation: ALK1: ; ALK2: ; a-MHC: alpha-myosin heavy chain; b-MHC: beta-
myosin heavy chain; MLC2v: myosin light chain 2v; GATA4: GATA binding
protein 4; Nkx2.5: NK2 transcription factor related, locus 5; NCX: sodium calcium
exchanger; SERCA-2a: sarcoplasmic reticulum Calcium ATPase 2a; RyR2:
ryanodine receptor 2.
doi:10.1371/journal.pone.0019787.t001
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Beating outgrowths from D3 murine ESC-derived embryoid
bodies (day 8) and human iPSC- derived embryoid bodies (day 30)
were micro-surgically dissected using a glass knife, followed by
incubation in collagenase B (1 mg/ml)(Roche) at 37uC for
30 minutes with occasional dispersion by pipetting up and down.
Single cardiomyocytes were then plated on glass coverslips for
confocal calcium imaging [2,4,44,45]. To assess calcium-handling
properties, ESC-derived cardiomyocytes were loaded with 5 mM
Rhod-2 AM (Invitrogen) for 45 min at 37uC in Tyrode solution
containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM
CaCl2, 10 mM glucose and 10 mM HEPES at pH 7.4. Calcium
transients of single ESC-derived cardiomyocytes were recorded
using a confocal imaging system (Olympus Fluoview System
version 4.2 FV300 TIEMPO) mounted on an upright Olympus
microscope (IX71) with temporal resolution of the line scan at 274
frames per second. Signals were then quantified as the back-
ground-subtracted fluorescence intensity changes normalized to
the background-subtracted baseline fluorescence using Image J
software.
Statistical Analysis
Continuous variables are expressed as mean 6 SEM. Statistical
comparisons were performed using Student’s t-test. Calculations
were performed with GraphPad Prism 5 (GraphPad, La Jolla,
CA). A P-value ,0.05 was considered statistically significant.
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